uniQure’s AMT-130 Receives FDA’s Fast Track Designation for Huntington’s Disease

 uniQure’s AMT-130 Receives FDA’s Fast Track Designation for Huntington’s Disease

uniQure’s AMT-130 Receives FDA’s Fast Track Designation for Huntington’s Disease

Shots:

  • The FDA’s FT designation follows P-I/II study assessing AMT-130 in patients with Huntington’s disease with an expected initiation in H2’19
  • FDA grant Fast Track designation to facilitate the development & and expedite the review of drugs to treat serious conditions and fill an unmet medical need
  • AMT-130 is an AVV5 gene therapy one-time administered carrying a DNA cassette encoding a microRNA that non-selectively lowers or knocks-down human huntingtin protein and targets highly toxic exon1 protein fragment 

Click here to read full press release/ article | Ref: uniQure | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post